Prognosis of Patient Evaluated for Palliative Radiotherapy

NCT03797755 | Unknown

• 1 other identifier: NTWC_Onc_2019
• Study Type: observational
• Target: 450
• Locations: 1 country
• Sites: 1

Brief Summary

Many patients with incurable cancer will receive palliative oncological treatment before their death, and radiotherapy (RT) is an important element of this. The aim of palliative RT is to alleviate symptoms and improve quality of life. An accurate and practical survival prediction model for metastatic cancer patient receiving palliative RT can assist the decision making (ranging from best supportive treatment alone for expected short survival, to dose escalation for potential better disease control). The available survival prediction models (such Survival Prediction Score using Number of Risk Factors by Chow et al and TEACHH model) have been developed in the Western world. We therefore perform a prospective observational study 1) to assess the overall survival of patients evaluated for palliative RT at a tertiary hospital in Hong Kong, and 2) to validate the prognostic score systems in our population.

Conditions

Cancer; Radiotherapy

Keywords

survival; cancer; palliative; radiotherapy; prognosis

Outcome Measures

Primary Outcomes (1)

• Overall Survival

  Overall Survival in the studied population

  1 year

Secondary Outcomes (3)

• Overall Survival in Each Indication of Palliative Radiotherapy

  3, 6, 9, 12 months

• Overall Survival by Survival Prediction Model (NRF)

  3, 6, 9, 12 months

• Overall Survival by Survival Prediction Model (TEACHH)

  3, 6, 9, 12 months

Study Arms (1)

Palliative Cancer Patients

Stage IV cancer patients evaluated for palliative radiotherapy.

Radiation: palliative radiotherapy

Interventions

palliative radiotherapy RADIATION

Radiotherapy for palliating symptoms in stage IV cancer patients

Palliative Cancer Patients

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Stage IV cancer patients evaluated for palliative radiotherapy in Tuen Mun Hospital

You may qualify if:

• All adult patients with stage IV cancer who are referred for palliative RT in Tuen Mun Hospital, including both inpatients and outpatients.

You may not qualify if:

• Patients who have received palliative RT before (i.e. not the first course palliative RT), have non-metastatic disease, are misclassified as palliative patients.

Sponsors & Collaborators

• Tuen Mun Hospital: lead

Study Sites (1)

Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun

Hong Kong, Hong Kong

RECRUITING

Related Publications (7)

• Chow E, Harth T, Hruby G, Finkelstein J, Wu J, Danjoux C. How accurate are physicians' clinical predictions of survival and the available prognostic tools in estimating survival times in terminally ill cancer patients? A systematic review. Clin Oncol (R Coll Radiol). 2001;13(3):209-18. doi: 10.1053/clon.2001.9256.

  PMID: 11527298 BACKGROUND

• Christakis NA, Lamont EB. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ. 2000 Feb 19;320(7233):469-72. doi: 10.1136/bmj.320.7233.469.

  PMID: 10678857 BACKGROUND

• Gripp S, Mjartan S, Boelke E, Willers R. Palliative radiotherapy tailored to life expectancy in end-stage cancer patients: reality or myth? Cancer. 2010 Jul 1;116(13):3251-6. doi: 10.1002/cncr.25112.

  PMID: 20564632 BACKGROUND

• Chow E, Abdolell M, Panzarella T, Harris K, Bezjak A, Warde P, Tannock I. Predictive model for survival in patients with advanced cancer. J Clin Oncol. 2008 Dec 20;26(36):5863-9. doi: 10.1200/JCO.2008.17.1363. Epub 2008 Nov 17.

  PMID: 19018082 BACKGROUND

• Peppercorn JM, Smith TJ, Helft PR, Debono DJ, Berry SR, Wollins DS, Hayes DM, Von Roenn JH, Schnipper LE; American Society of Clinical Oncology. American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol. 2011 Feb 20;29(6):755-60. doi: 10.1200/JCO.2010.33.1744. Epub 2011 Jan 24.

  PMID: 21263086 BACKGROUND

• Chow E, James JL, Hartsell W, Scarantino CW, Ivker R, Roach M III, Suh JH, Demas W, Konski A, Bruner DW. Validation of a Predictive Model for Survival in Patients With Advanced Cancer: Secondary Analysis of RTOG 9714. World J Oncol. 2011 Aug;2(4):181-190. doi: 10.4021/wjon325w. Epub 2011 Aug 24.

  PMID: 29147245 BACKGROUND

• Krishnan MS, Epstein-Peterson Z, Chen YH, Tseng YD, Wright AA, Temel JS, Catalano P, Balboni TA. Predicting life expectancy in patients with metastatic cancer receiving palliative radiotherapy: the TEACHH model. Cancer. 2014 Jan 1;120(1):134-41. doi: 10.1002/cncr.28408. Epub 2013 Oct 2.

  PMID: 24122413 BACKGROUND

MeSH Terms

Conditions

Neoplasms

Study Officials

• Shing Fung Lee, MBBS (HK), FRCR (UK)

  Department of Clinical Oncology, New Territory West Cluster, Hospital Authority, Hong Kong

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Shing Fung Lee, MBBS (HK), FRCR (UK)

CONTACT

852 2468 5087; leesfm@ha.org.hk

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Year
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident Specialist

Study Record Dates

• First Submitted: January 7, 2019
• First Posted: January 9, 2019
• Study Start: January 1, 2019
• Primary Completion: December 31, 2019
• Study Completion: December 31, 2019
• Last Updated: January 9, 2019

Record last verified: 2019-01

Data Sharing

• IPD Sharing: Will share
• Shared Documents: ANALYTIC CODE
• Time Frame: After publication.

Locations

HK (1)